News Releases


May 20, 2019

Processa Pharmaceuticals Announces Today That They Will Be Presenting At The Jeffries 2019 Global Healthcare Conference On Friday, June 7th, 2019

March 11, 2019

Processa Pharmaceuticals Announces Today That They Will Be Presenting At The Cowen Conference On Wednesday

January 29, 2019

Processa Pharmaceuticals Announces First Patient Dosed In Clinical Trial To Evaluate The Safety And Tolerability Of Pcs-499 For The Treatment Of Necrobiosis Lipoidica

January 9, 2019

Processa Pharmaceuticals Amounces Presentation of PCS499 Data at the Annual Meeting of American Academy of Dermatology

December 6, 2018

Processa Pharmaceuticals Announces Up-listing to OTCQB Market

October 2, 2018

Processa Pharmaceuticals Receives Fda Clearance Of Ind To Begin Phase 2 Clinical Development Of Pcs-499 In Necrobiosis Lipoidica Patients

September 10, 2018

Processa Pharmaceuticals Appoints James Stanker As Chief Financial Officer

June 22, 2018

Processa Pharmaceuticals Receives Orphan Designation Status For PCS499 In Necrobiosis Lipoidica From The Food And Drug Administration (FDA)

June 1, 2018

Processa Pharmaceuticals Raises $6.88 Million from Pivate Placements

May 29, 2018

Processa Pharmaceuticals, Inc. to Present at the 8th Annual LD Micro Invitational

Mar 22, 2018

Processa licenses compound from Concert

Mar 21, 2018

Processa Pharmaceuticals Has Been Assigned The License For The Clinical Stage Compound Ctp-499 And Plans To Develop The Drug In Multiple Unmet Medical Need Conditions

Mar 3, 2018

Processa Pharmaceuticals Announces Attendance at 2018 ROTH Conference
> Download Processa Pharmaceuticals Roth Conference Presentaiton

Dec 11, 2017

Processa Pharmaceuticals Announces Reverse Stock Split and Launches New Website

Oct 5, 2017

Heatwurx, Inc. Closes Asset Purchase Transaction with Promet Therapeutics, LLC

Oct 3, 2017

Heatwurx, Inc. Announces Execution Of Definitive Asset Purchase Agreement With Promet Therapeutics, LLC

July 17, 2017

Heatwurx Announces Letter Of Intent With Promet Therapeutics, LLC Relating To A Reverse Merger